Cronos Group/$CRON

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Cronos Group

Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.

Ticker

$CRON
Sector
Primary listing

Employees

459

Headquarters

Stayner, Canada

Cronos Group Metrics

BasicAdvanced
$965M
52.44
$0.05
1.50
-

What the Analysts think about Cronos Group

Analyst ratings (Buy, Hold, Sell) for Cronos Group stock.

Bulls say / Bears say

Cronos reported net revenue of $33.6 million for Q1 2025, a 33% year-over-year increase on a constant currency basis, driven by higher cannabis flower sales in Israel and other markets, as well as greater extract sales in Canada.
Adjusted gross profit increased 218% to $14.3 million, pushing adjusted gross margin up to 44% from 18%. This reflects improved production efficiency, better pricing, and lower direct costs.
The company maintained a strong liquidity position with cash and short-term investments totaling $838.1 million as of March 31, 2025, supporting continued expansion and strategic initiatives.
Regulatory uncertainty in Israel remains, as the Minister of Economy aims to enforce a possible 165% anti-dumping duty on Canadian medical cannabis despite a veto from the Minister of Finance. This could lead to higher costs and reduced market access.
Cronos' expansion into the U.S. market depends on federal legalization; with no clear timeline for lifting prohibition, the company cannot exercise its 5.9% PharmaCann acquisition option yet, limiting potential growth in the U.S.
Continued geopolitical instability in the Middle East could disrupt operations, supply chains, and patient demand in Israel. Israel is a crucial market, making up 29% of Q1 revenue.
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.

Cronos Group Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Cronos Group Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CRON

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy Cronos Group stock | $CRON Share Price | Lightyear